The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases
Authors:
- Sylwia SudołSSSylwia Sudoł
- Agnieszka CiosACAgnieszka Cios
- Magdalena Jastrzębska-WięsekMJMagdalena Jastrzębska-Więsek
- Ewelina Honkisz-OrzechowskaEHEwelina Honkisz-Orzechowska
- Barbara MordylBMBarbara Mordyl
- Natalia Wilczyńska-ZawalNWNatalia Wilczyńska-Zawal
- Grzegorz SatałaGSGrzegorz Satała
- Katarzyna Kucwaj-BryszKKKatarzyna Kucwaj-Brysz
- Anna PartykaAPAnna Partyka
- Gniewomir LataczGLGniewomir Latacz
- Agnieszka Olejarz-MaciejAOAgnieszka Olejarz-Maciej
- Anna WesołowskaAWAnna Wesołowska
Open Access
- 5 October 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10773
Abstract
Among the serotonin receptors, one of the most recently discovered 5-HT6 subtype is an important protein target and its ligands may play a key role in the innovative treatment of cognitive disorders. However, none of its selective ligands have reached the pharmaceutical market yet. Recently, a new chemical class of potent 5-HT6 receptor agents, the 1,3,5-triazine-piperazine derivatives, has been synthesized. Three members, the ortho and meta dichloro- (1,2) and the unsubstituted phenyl (3) derivatives, proved to be of special interest due to their high affinities (1,2) and selectivity (3) toward 5-HT6 receptor. Thus, a broader pharmacological profile for 1–3, including comprehensive screening of the receptor selectivity and drug-like parameters in vitro as well as both, pharmacokinetic and pharmacodynamic properties in vivo, have been investigated within this study. A comprehensive analysis of the obtained results indicated significant procognitive-like activity together with beneficial drug-likeness in vitro and pharmacokinetics in vivo profiles for both, (RS)-4-[1-(2,3-dichlorophenoxy)propyl]-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (2) and (RS)-4-(4-methylpiperazin-1-yl)-6-(1-phenoxypropyl)-1,3,5-triazin-2-amine (3), but insensibly predominant for compound 2. Nevertheless, both compounds (2 and 3) seem to be good Central Nervous System drug candidates in search for novel therapeutic approach to dementia diseases, based on the 5-HT6 receptor target.Keywords
Funding Information
- Narodowe Centrum Nauki (UMO-2018/31/B/NZ7/02160)
This publication has 53 references indexed in Scilit:
- Troubleshooting the dichlorofluorescein assay to avoid artifacts in measurement of toxicant-stimulated cellular production of reactive oxidant speciesJournal of Pharmacological and Toxicological Methods, 2013
- 5‐HT6receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanismsBritish Journal of Pharmacology, 2012
- Is the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia?Schizophrenia Bulletin, 2011
- 5-HT6 receptor and cognitionCurrent Opinion in Pharmacology, 2011
- An update on the role of the 5-hydroxytryptamine6 receptor in cognitive functionNeuropharmacology, 2008
- The Novel α7 Nicotinic Acetylcholine Receptor Agonist N-[(3 R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Cholinesterase Inhibitors Ameliorate Behavioral Deficits Induced by MK-801 in MiceNeuropsychopharmacology, 2005
- A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP AccumulationBiochemical and Biophysical Research Communications, 1993
- A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral dataBehavioural Brain Research, 1988
- Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the ratPharmacology Biochemistry and Behavior, 1986